688180 君實生物
按盤價 
29.420 -1.000 (-3.287%) | 2024/09 - 九個月 人民幣(K¥) | 與去年同期 比較 | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | 2020/12 人民幣(K¥) | ||
| 營業總收入 | 1,271,200 | 28.87% | 1,502,550 | 1,453,493 | 4,024,841 | 1,594,897 | |
| 減：營業總成本 | 2,261,152 | -8.80% | 3,811,860 | 4,102,931 | 4,728,260 | 3,307,229 | |
| 其中:營業成本 | 325,339 | -3.42% | 540,976 | 504,308 | 1,244,540 | 372,531 | |
| 財務費用 | 7,539 | -113.62% | (67,086) | (80,955) | 31,366 | 21,186 | |
| 資產減值損失 | (3,642) | -89.67% | (126,314) | (21,974) | (13,647) | (4,227) | |
| 公允價值變動收益 | (30,053) | -34.45% | (149,177) | (9,277) | 112,933 | 46,042 | |
| 投資收益 | (17,148) | -61.78% | 73,990 | (41,932) | (47,187) | (5,621) | |
| 其中：對聯營企業和合營企業的投資收益 | (24,445) | -50.22% | (60,485) | (71,031) | (48,463) | (3,805) | |
| 營業利潤 | (969,121) | -38.68% | (2,457,442) | (2,665,914) | (558,275) | (1,656,082) | |
| 利潤總額 | (984,644) | -38.75% | (2,491,695) | (2,677,184) | (595,000) | (1,672,429) | |
| 減：所得稅費用 | 4,082 | -107.79% | 43,995 | (93,107) | 135,533 | (3,822) | |
| 淨利潤 | (988,726) | -36.42% | (2,535,689) | (2,584,077) | (730,534) | (1,668,607) | |
| 減：非控股權益 | (61,957) | -58.22% | (252,257) | (196,028) | (9,624) | -0 | |
| 股東淨利潤 | (926,769) | -34.12% | (2,283,432) | (2,388,050) | (720,910) | (1,668,607) | |
市場價值指標 | |||||||
| 每股收益 (元) * | -0.940 | -34.27% | -2.320 | -2.600 | -0.810 | -2.030 | |
| 每股派息 (元) * | -- | -- | -- | -- | -- | -- | |
| 每股淨資產 (元) * | 6.262 | -23.46% | 7.260 | 9.650 | 8.720 | 6.679 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 15/11/2024 16:29 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
